Agilent Technologies Introduces HaloPlex Exome Kits and SureCall Software
(ENP Newswire Via Acquire Media NewsEdge) ENP Newswire - 22 February 2013
Release date- 21022013 - Agilent Technologies Inc. (NYSE: A) today expanded its portfolio of target-enrichment products with the introduction of HaloPlex exome kits and SureCall software.
The new additions are designed to complement Agilent's Web-based SureDesign and custom HaloPlex gene panels to provide a complete, integrated workflow.
'These products simplify the sequencing of clinical research samples,' said Olle Ericsson, Agilent director of marketing for DNA sequencing. 'The HaloPlex Exome delivers streamlined capture of all coding exons, with low input sample requirements, on all Illumina sequencing platforms. Together with SureDesign, and the SureCall software, these products constitute a very comprehensive clinical research solution for target enrichment.'
The HaloPlex exome kit comprises about 2.5 million probes to provide efficient and comprehensive coverage of the coding regions of the human genome with minimal hands-on time and requires only 200 ng of input DNA.
'The HaloPlex exome provides an easy workflow for all-exon analysis enabling short turnaround sequencing with low DNA input amounts,' said Dr. Wilfred van IJcken, assistant professor at Erasmus MC and an early access user who also will present at the 14th annual Advances in Genome Biology and Technology meeting, Feb. 20-23, in Marco Island, Fla.
SureDesign, which has logged over 15,000 designs since it was launched in October, enables clinical researchers to create a custom panel tailored to their needs. With this interface, researchers can quickly generate exceptionally flexible designs for high-performance, targeted resequencing, using Agilent's HaloPlex and SureSelect systems. In just three simple steps, researchers can create custom sequencing panels tailored to their specific projects. To provide confidence in the analysis, any custom gene-sequencing panel can be created based on the 2.5 million probes from the HaloPlex exome kit.
SureCall data analysis software is designed to maximize clinical laboratory throughput by dramatically simplifying the analysis workflow for next-generation sequencing data. The software is fast, reliable and easy to use, with a three-step workflow process that translates raw data into a report with genetic variants classified and ranked in a matter of hours. Its end-to-end capabilities make it more cost effective than other methods and enable clinical researchers to focus on their results rather than cumbersome analysis processes by eliminating the expensive, time-consuming data analysis bottleneck. To download the new software free of charge, visit www.agilent.com/genomics/surecall.
About Agilent in Genomics
Agilent a global leader in target enrichment for next-generation sequencing and genomic microarrays. The Agilent SureSelect and HaloPlex target-enrichment systems enable researchers to easily choose which segments of a genome to sequence, avoiding the time and expense needed to sequence the entire genome. HaloPlex and its same-day sample-to-sequencer workflow is well suited for next-generation desktop sequencers, whereas SureSelect's ability to accurately capture whole exomes and whole methylomes in a single reaction pairs well with high-throughput next-generation sequencing systems. These are just two products arising from Agilent's expertise in synthesizing custom complex mixtures of long oligonucleotide gained in microarray manufacturing.
Additional product lines built on this core technology include microarrays for genome-wide measurement of gene expression and for comparative genomics hybridization, as well as SureFISH, a highly specific and sensitive oligonucleotide fluorescent in situ hybridization product line. In addition to oligonucleotide-based products, Agilent offers a microfluidic bioanalyzer to measure sample quality, a target-enrichment tool to speed next-generation sequencing, and a full set of reagents, hardware, methods and bioinformatics software for genomic experiments.
[Editorial queries for this story should be sent to email@example.com]
((Comments on this story may be sent to firstname.lastname@example.org))
(c) 2013 Electronic News Publishing -
[ Back To IBM News 's Homepage ]